Patent Application for Antisense Oligonucleotide Targeting TDP-43 mRNA

ChangeBridge: Patent Apps - Biotech (C12N)

Published May 26th, 2023

Detected March 27th, 2026

Summary

The USPTO has published a patent application (US20260085310A1) filed by NIPPON SHINYAKU CO., LTD. The application describes an antisense oligonucleotide targeting TDP-43 mRNA or pre-mRNA for potential therapeutic use. The filing date was May 26, 2023.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published patent application US20260085310A1, filed by NIPPON SHINYAKU CO., LTD. The application details an antisense oligonucleotide designed to target TDP-43 mRNA or pre-mRNA, consisting of 15 to 22 nucleotides complementary to specific regions of SEQ ID NO: 1. This relates to potential treatments for conditions involving TDP-43.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, companies in the pharmaceutical and biotechnology sectors, particularly those involved in oligonucleotide therapeutics or neurodegenerative disease research, should be aware of this filing as it pertains to intellectual property in this area. No compliance actions or deadlines are associated with this patent application publication itself.

Source document (simplified)

← USPTO Patent Applications

ANTISENSE OLIGONUCLEOTIDE TARGETING TDP-43 MRNA OR PRE-MRNA

Application US20260085310A1 Kind: A1 Mar 26, 2026

Assignee

NIPPON SHINYAKU CO., LTD.

Inventors

Akihiro MURATA, Mikiya FUJIWARA

Abstract

In the present specification, an antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 1 to 102, 159 to 842, 879 to 1822, and 1874 to 4182 from the 5′ end of a base sequence of SEQ ID NO: 1 is provided.